HK1199693A1 - Antibacterial compounds and methods for use - Google Patents

Antibacterial compounds and methods for use Download PDF

Info

Publication number
HK1199693A1
HK1199693A1 HK15100101.9A HK15100101A HK1199693A1 HK 1199693 A1 HK1199693 A1 HK 1199693A1 HK 15100101 A HK15100101 A HK 15100101A HK 1199693 A1 HK1199693 A1 HK 1199693A1
Authority
HK
Hong Kong
Prior art keywords
methods
antibacterial compounds
gram
compounds
wild
Prior art date
Application number
HK15100101.9A
Other languages
English (en)
Chinese (zh)
Inventor
Branstrom Arthur
Prasad Venkata Nagendra Josyula Vara
Andrew Arnold Michael
I. Gerasyuto Aleksey
Karp Gary
Wang Jiashi
David Baird John
Chen Guangming
Ginzburg Olya
Yang Tianle
Wesley Smith Sean
Peddi Srinivasa
G. Woll Matthew
Zhang Xiaoyan
Zhang Nanjing
Qi Hongyan
Narasimhan Jana
Original Assignee
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics, Inc. filed Critical Ptc Therapeutics, Inc.
Publication of HK1199693A1 publication Critical patent/HK1199693A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15100101.9A 2011-08-29 2012-08-29 Antibacterial compounds and methods for use HK1199693A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528599P 2011-08-29 2011-08-29
US61/528,599 2011-08-29
PCT/US2012/052922 WO2013033258A1 (en) 2011-08-29 2012-08-29 Antibacterial compounds and methods for use

Publications (1)

Publication Number Publication Date
HK1199693A1 true HK1199693A1 (en) 2015-07-17

Family

ID=47756844

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100101.9A HK1199693A1 (en) 2011-08-29 2012-08-29 Antibacterial compounds and methods for use

Country Status (14)

Country Link
US (1) US9409905B2 (https=)
EP (1) EP2750504A4 (https=)
JP (1) JP2014525453A (https=)
KR (1) KR20140097118A (https=)
CN (1) CN103889224B (https=)
AU (1) AU2012301953C1 (https=)
BR (1) BR112014004515A2 (https=)
CA (1) CA2846663A1 (https=)
CL (1) CL2014000469A1 (https=)
HK (1) HK1199693A1 (https=)
IL (1) IL231060A (https=)
MX (1) MX2014002298A (https=)
WO (1) WO2013033258A1 (https=)
ZA (1) ZA201402248B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1199792A1 (en) * 2011-08-29 2015-07-24 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
WO2014139388A1 (en) * 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014157382A1 (ja) * 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds
WO2016039937A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds
WO2016109706A1 (en) * 2014-12-31 2016-07-07 Ptc Therapeutics, Inc. Fused polycyclic 2-pyridinone antibacterial compounds
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
JP7153645B2 (ja) * 2017-06-08 2022-10-14 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
CN107325080B (zh) * 2017-08-30 2020-05-12 延边大学 含三嗪或氨基胍结构的咔唑类衍生物的制备方法及其抗菌应用
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
CN108659091B (zh) * 2018-05-24 2020-07-03 烟台大学 夫西地酸衍生物及其合成制备方法和应用
JP2021534246A (ja) * 2018-08-16 2021-12-09 レクレオ ファーマシューティカルス アイエヌシー １，３，４，９−テトラヒドロ−２ｈ−ピリド［３，４−ｂ］インドール誘導体化合物及びその使用
CN109329290A (zh) * 2018-10-11 2019-02-15 四川省兰月科技有限公司 防治猕猴桃、柑橘黄化病的农药组合物
CN109485601B (zh) * 2018-12-23 2020-06-30 沧州普瑞东方科技有限公司 2,6-二卤吡啶-3-羧酸的合成方法
CN111521706A (zh) * 2020-05-11 2020-08-11 苏州必宜生物科技有限公司 一种快速检测血浆中头孢克肟浓度的方法
AU2022424463A1 (en) * 2021-12-28 2024-07-18 Adeka Corporation Aryl tetrahydropyridine derivative or salt thereof, pest control agent containing same, and method for use thereof
CN115960031B (zh) * 2023-01-06 2024-09-10 暨南大学 一种四氢异吲哚酮类化合物及其制备方法和应用
CN119569650A (zh) * 2024-12-05 2025-03-07 凯美克(上海)医药科技有限公司 一种7-溴-2-氯喹啉-4-醇的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3948903A (en) * 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US3954734A (en) 1974-01-21 1976-05-04 Parke, Davis & Company Novel antibacterial amide compounds and process means for producing the same
JPS5643288A (en) 1979-09-18 1981-04-21 Meiji Seika Kaisha Ltd Cephalosporin derivative and its preparation
JPS5651488A (en) 1979-10-02 1981-05-09 Meiji Seika Kaisha Ltd Penicillin derivative and its preparation
DE3338846A1 (de) * 1982-10-29 1984-05-03 Toyama Chemical Co. Ltd., Tokyo Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
GB8809481D0 (en) 1988-04-21 1988-05-25 Smith Kline French Lab Chemical compounds
IE911704A1 (en) * 1990-05-21 1991-12-04 Smith Kline French Lab Chemical compounds
DE19639817A1 (de) * 1996-09-27 1998-04-02 Hoechst Ag Verwendung von 1-Hydroxy-2-pyridonen zur Behandlung von Hautinfektionen
CN1231161A (zh) 1998-07-07 1999-10-13 邱泽国 全自动多功能超声波洗碗机
EP1343763A1 (en) 2000-11-20 2003-09-17 Bristol-Myers Squibb Company Pyrodone derivatives as ap2 inhibitors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ATE448784T1 (de) * 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CN101531631B (zh) 2002-02-14 2011-09-28 法玛西雅公司 作为p38map激酶调节剂的取代吡啶酮类
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
CN101171247A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
WO2006117762A2 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Antimicrobial agents
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
HK1199792A1 (en) * 2011-08-29 2015-07-24 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
CA2846655A1 (en) * 2011-08-29 2013-03-07 Arthur Branstrom Antibacterial compounds and methods for use

Also Published As

Publication number Publication date
US9409905B2 (en) 2016-08-09
NZ623063A (en) 2016-04-29
CA2846663A1 (en) 2013-03-07
AU2012301953C1 (en) 2016-11-03
EP2750504A4 (en) 2015-03-11
CN103889224A (zh) 2014-06-25
ZA201402248B (en) 2016-06-29
CL2014000469A1 (es) 2014-11-14
EP2750504A1 (en) 2014-07-09
CN103889224B (zh) 2017-05-24
JP2014525453A (ja) 2014-09-29
WO2013033258A1 (en) 2013-03-07
AU2012301953A1 (en) 2014-03-13
BR112014004515A2 (pt) 2017-03-28
IL231060A0 (en) 2014-03-31
US20150038437A1 (en) 2015-02-05
IL231060A (en) 2017-01-31
MX2014002298A (es) 2014-07-22
KR20140097118A (ko) 2014-08-06
AU2012301953B2 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
HK1199792A1 (en) Antibacterial compounds and methods for use
HK1199693A1 (en) Antibacterial compounds and methods for use
PH12014500429A1 (en) Antibacterial compounds and methods for use
WO2013122888A3 (en) Methods of treating bacterial infections
SG11201405829WA (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
IL229922B (en) Preparations for the treatment and prevention of Staphylococcus aureus infections and related conditions
ZA201301598B (en) Benzoxaborole derivatives for treating bacterial infections
SG11201504813XA (en) Mannose derivatives for treating bacterial infections
WO2012116010A3 (en) Antibiotic tolerance inhibitors
WO2013036783A3 (en) Methods for treating intrapulmonary infections
SG11201700621XA (en) Antibiotic compositions for treating bacterial infections
EP3273797A4 (en) Composition inhibiting gram-positive, pathogenic bacteria
EP3330275A4 (en) Novel aminoglycoside antibiotic effective against multidrug-resistant bacteria
WO2015024021A3 (en) Antibacterial compounds
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
WO2010123599A3 (en) Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
EP2916653A4 (en) ANTIBIOTIC PROCEDURES AND COMPOSITIONS FOR BACTERIAL INFECTIONS
EP2564835A4 (en) FAST DISSOLVING SOLID PHARMACEUTICAL FORM FOR THE TREATMENT OF BACTERIAL INFECTIONS
HUP1100495A2 (en) Synergistic biocontrol compounds against xanthomonas infections
WO2014057415A3 (en) Inhibitors of dna gyrase for the treatment of bacterial infections
EP3251682A4 (en) Compositions for treating infections caused by the mite demodex spp
EP2529728A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
WO2015063608A3 (en) Prevention and dispersion of biolfilm
AU2012900981A0 (en) Gram-negative bacterial infection therapy & prophylaxis
TH0901005768A (th) สารต้านเชื้อแบคทีเรียชนิดใหม่สำหรับรักษาการติดเชื้อแบคทีเรียแกรมบวก